Life Sciences In The Crosshairs

Virtually one hundred percent of general counsel in the U.S. economy’s burgeoning life sciences sector report litigation and regulation as their top concerns, and for good reason. How recent changes in SEC “enforcement triage” and the dearth of some previously attractive targets for plaintiff attorneys have put these companies in the crosshairs of both, and what companies can do about it.